Similarly, supplementation with the same quantity of EVs from MC38‐Coro1a (MC38‐Coro1a‐EVs) and from MC38‐Coro1a‐K233R cells (MC38‐Coro1a‐K233R‐EVs) abolished the growth priority of MC38‐Coro1a‐K233R tumour and equally prolonged the survival (Figure 7d, e). The gene discussed is CORO1A; the disease is neoplasm.